FDA
-
-
-
-
-
-
-
Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results
-
-
-
-
-
-
-
Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting
-
-
-
-
-
-
-
Eupraxia reports positive tissue health data from EoE trial
-
-
-
-
-
-
-
Eupraxia reports sustained 12-month results from eosinophilic esophagitis trial
-
-
-
-
-
-
-
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders
-
-
-
-
-
-
-
Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
-
-
-
-
-
-
-
Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million
-
325,894 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

